文献速递糖尿病

GLP-1类药物在1型糖尿病中的应用:疗效、安全性与患者选择

GLP‐1–Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-10-28

本叙述性综述评估GLP-1受体激动剂及GIP/GLP-1双受体激动剂tirzepatide作为1型糖尿病胰岛素辅助治疗的证据,重点关注超重或肥胖人群的获益-风险平衡。分析显示利拉鲁肽可降低体重和胰岛素需求但增加低血糖和酮症风险,而司美格鲁肽和tirzepatide在肥胖患者中重新引发关注。

要点

  • GLP-1类药物用于T1D需以肥胖成人为主,进行表型导向的患者选择。
  • 胰岛素需充分下调以预防低血糖,同时维持足够剂量以抑制酮体生成。
  • 胃肠道不良事件可能通过减少碳水摄入和脱水进一步破坏代谢平衡。

核心结论

  • 当前证据支持以1型糖尿病合并肥胖的成人为主的表型导向治疗策略,需配合仔细的患者选择、个体化胰岛素调整、血糖和酮体监测以及结构化患者教育。
  • 核心临床问题已从GLP-1类药物对T1D是否有效,转变为哪些患者最可能获得有利的获益-风险平衡以及如何安全使用这些药物。

研究设计与样本

  • 本叙述性综述检视了利拉鲁肽、司美格鲁肽和tirzepatide在1型糖尿病中的证据,重点关注体重、胰岛素需求、低血糖、酮症、糖尿病酮症酸中毒和胃肠道耐受性。

主要发现

  • 早期利拉鲁肽试验显示体重和胰岛素需求均下降,但引发了低血糖和酮症方面的担忧。
  • 司美格鲁肽和tirzepatide因其更强的体重和胰岛素需求效应,在肥胖的1型糖尿病患者中重新引起对肠促胰素治疗的关注。
  • 司美格鲁肽和tirzepatide的显著效应带来了临床安全挑战:必须充分下调胰岛素以预防低血糖,同时保持足够的胰岛素化以抑制脂肪分解和酮体生成。
  • 胃肠道不良事件可能通过减少碳水化合物摄入和脱水进一步破坏上述代谢平衡。

临床怎么用

  • 使用GLP-1类药物时需进行个体化胰岛素剂量下调,同时监测血糖和酮体水平。
  • 应优先选择合并肥胖的1型糖尿病成人患者,并配合结构化患者教育以确保安全使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims To critically examine the evolving evidence on glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide as adjuncts to insulin therapy in type 1 diabetes (T1D), with particular emphasis on their benefit–risk balance in individuals with overweight or obesity. Materials and Methods This narrative review examines evidence on liraglutide, semaglutide and tirzepatide in T1D, focusing on effects on body weight and insulin requirements, alongside hypoglycaemia, ketosis, diabetic ketoacidosis and gastrointestinal tolerability. Results Early trials with liraglutide demonstrated reductions in body weight and insulin requirements but raised concerns regarding hypoglycaemia and ketosis. More recently, semaglutide and tirzepatide have renewed interest in incretin-based therapy in T1D, particularly among individuals with obesity. Their greater effects on weight and insulin requirements introduce a clinically important safety challenge: insulin must be reduced sufficiently to prevent hypoglycaemia while maintaining adequate insulinization to suppress lipolysis and ketogenesis. Gastrointestinal adverse events may further destabilize this balance through reduced carbohydrate intake and dehydration. Conclusion Current evidence supports a phenotype-directed approach centred primarily on adults with T1D and obesity, accompanied by careful patient selection, individualised insulin adjustment, glucose and ketone monitoring, and structured patient education. The clinical question has shifted from whether GLP-1–based therapies are effective in T1D to which patients are most likely to achieve a favourable benefit–risk balance and how these therapies can be used safely.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:GLP‐1–Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。